• Search
      • Search Interactions Search Categories
    • Browse
      • Browse Categories Browse Sources
    • Information
      • About Publications Interaction Types & Directionalities Interaction Score & Query Score API Documentation FAQ Known Data Clients News Contact
    • Downloads
      • Data Source Code

AXITINIB Drug Record

  • Summary
  • Interactions
  • Claims
  • AXITINIB chembl:CHEMBL1289926 ApprovedAntineoplastic

    Alternate Names:

    AG-13736
    INLYTA
    AXITINIB
    AG-013736
    AXITINIBUM
    AG 013736
    N-METHYL-2-({3-[(E)-2-(PYRIDIN-2-YL)VINYL]-1H-INDAZOL-6-YL}SULFANYL)BENZAMIDE
    INLYTA®
    AG013736
    drugbank:06626
    chemidplus:319460-85-0
    chembl:CHEMBL1289926
    rxcui:1242999
    pubchem.compound:6450551

    Drug Info:

    FDA Approval Renal cell carcinoma
    Drug Class Kinase Inhibitors
    FDA Approval approved
    Drug Class Small molecule
    Drug Indications antineoplastic agent
    Pharmaceutical Developer Pfizer
    Pharmaceutical Developer Novartis
    Source Reported Drug Name(s) Axitinib/AG013736/Inlyta
    Drug Class Kinase Inhibitor
    Drug Categories benzoates
    Drug Categories acids, carbocyclic
    Drug Categories amides
    Drug Categories benzamides and benzamide derivatives
    Drug Categories benzene derivatives
    Drug Categories cytochrome p-450 cyp3a substrates
    Drug Categories cytochrome p-450 cyp3a4 substrates with a narrow therapeutic index
    Drug Categories cytochrome p-450 cyp3a5 substrates
    Drug Categories cytochrome p-450 substrates
    Drug Categories heterocyclic compounds, fused-ring
    Drug Categories indazoles
    Drug Categories kinase inhibitor
    Drug Categories oatp1b1/slco1b1 inhibitors
    Drug Categories p-glycoprotein inhibitors
    Drug Categories p-glycoprotein substrates
    Drug Categories receptor tyrosine kinase inhibitors
    Drug Categories tyrosine kinase inhibitors
    Drug Categories ugt1a1 substrates
    (10 More Sources)

    Publications:

    Maitland ML et al., 2010, Vascular endothelial growth factor pathway., Pharmacogenet Genomics
    Cohen et al., 2008, Axitinib is an active treatment for all histologic subtypes of advanced thyroid cancer: results from a phase II study., J. Clin. Oncol.
    Pemovska T et al., 2015, Axitinib effectively inhibits BCR-ABL1(T315I) with a distinct binding conformation., Nature
    Zientek MA et al., 2016, In Vitro Kinetic Characterization of Axitinib Metabolism., Drug Metab Dispos
    Ehmann F et al., 2014, European Medicines Agency initiatives and perspectives on pharmacogenomics., Br J Clin Pharmacol
    Escudier B et al., 2015, Genotype Correlations With Blood Pressure and Efficacy From a Randomized Phase III Trial of Second-Line Axitinib Versus Sorafenib in Metastatic Renal Cell Carcinoma., Clin Genitourin Cancer
  • AXITINIB   PDGFB

    Interaction Score: 1.01

    Interaction Types & Directionality:
    inhibitor (inhibitory)

    Interaction Info:
    Reported Cancer Type Prostate

    PMIDs:
    None found


    Sources:
    CancerCommons

  • AXITINIB   FLT1

    Interaction Score: 0.45

    Interaction Types & Directionality:
    inhibitor (inhibitory)

    Interaction Info:
    Reported Cancer Type Prostate
    Mechanism of Interaction Vascular endothelial growth factor receptor inhibitor
    Direct Interaction yes

    PMIDs:
    20124951 18541897


    Sources:
    CancerCommons MyCancerGenomeClinicalTrial PharmGKB TdgClinicalTrial DrugBank TALC MyCancerGenome ChemblInteractions

  • AXITINIB   FLT4

    Interaction Score: 0.36

    Interaction Types & Directionality:
    inhibitor (inhibitory)

    Interaction Info:
    Reported Cancer Type Prostate
    Direct Interaction yes
    Mechanism of Interaction Vascular endothelial growth factor receptor inhibitor

    PMIDs:
    18541897


    Sources:
    CancerCommons MyCancerGenomeClinicalTrial TdgClinicalTrial DrugBank TALC MyCancerGenome ChemblInteractions

  • AXITINIB   KDR

    Interaction Score: 0.32

    Interaction Types & Directionality:
    inhibitor (inhibitory)

    Interaction Info:
    Specific Action of the Ligand Inhibition
    Endogenous Drug? False
    Direct Interaction? True

    PMIDs:
    20124951 18541897


    Sources:
    CancerCommons MyCancerGenomeClinicalTrial PharmGKB TdgClinicalTrial TTD DrugBank TALC MyCancerGenome GuideToPharmacology ChemblInteractions

  • AXITINIB   VHL

    Interaction Score: 0.24

    Interaction Types & Directionality:
    n/a

    Interaction Info:
    Alteration VHL:.
    Drug family [VEGFR inhibitor]
    combination therapy [Sorafenib,Sunitinib,Bevacizumab,Axitinib]

    PMIDs:
    None found


    Sources:
    CGI

  • AXITINIB   ABL1

    Interaction Score: 0.22

    Interaction Types & Directionality:
    n/a

    Interaction Info:
    Alteration ABL1:T315I
    Drug family VEGFR inhibitor

    PMIDs:
    25686603


    Sources:
    PharmGKB CIViC CGI

  • AXITINIB   KIT

    Interaction Score: 0.21

    Interaction Types & Directionality:
    inhibitor (inhibitory)

    Interaction Info:
    Trial Name axitinib, AG-013736
    Novel drug target Established target
    Reported Cancer Type Prostate

    PMIDs:
    None found


    Sources:
    CancerCommons TdgClinicalTrial TALC MyCancerGenome

  • AXITINIB   UGT1A1

    Interaction Score: 0.21

    Interaction Types & Directionality:
    n/a

    Interaction Info:

    PMIDs:
    26512042


    Sources:
    PharmGKB

  • AXITINIB   PDGFRB

    Interaction Score: 0.14

    Interaction Types & Directionality:
    inhibitor (inhibitory)

    Interaction Info:
    Notes
    Trial Name axitinib, AG-013736
    Novel drug target Established target

    PMIDs:
    None found


    Sources:
    TdgClinicalTrial TALC MyCancerGenome

  • AXITINIB   PLK4

    Interaction Score: 0.14

    Interaction Types & Directionality:
    inhibitor (inhibitory)

    Interaction Info:
    Specific Action of the Ligand Inhibition
    Endogenous Drug? False
    Direct Interaction? False

    PMIDs:
    None found


    Sources:
    GuideToPharmacology

  • AXITINIB   CYP3A5

    Interaction Score: 0.08

    Interaction Types & Directionality:
    n/a

    Interaction Info:

    PMIDs:
    24433361


    Sources:
    PharmGKB

  • AXITINIB   PDGFRA

    Interaction Score: 0.06

    Interaction Types & Directionality:
    n/a

    Interaction Info:
    Trial Name axitinib, AG-013736
    Novel drug target Established target

    PMIDs:
    None found


    Sources:
    TdgClinicalTrial

  • AXITINIB   HIF1A

    Interaction Score: 0.06

    Interaction Types & Directionality:
    n/a

    Interaction Info:

    PMIDs:
    25816720


    Sources:
    PharmGKB

  • AXITINIB   YES1

    Interaction Score: 0.02

    Interaction Types & Directionality:
    n/a

    Interaction Info:

    PMIDs:
    None found


    Sources:
    DTC

  • DrugBank: DB06626

    • Version: 5.1.7

    Alternate Names:
    AXITINIB DrugBank Drug Name
    319460-85-0 CAS Number
    Inlyta Drug Brand

    Drug Info:
    Drug Type small molecule
    Drug Groups approved
    Drug Groups investigational

    Publications:
    Cohen et al., 2008, Axitinib is an active treatment for all histologic subtypes of advanced thyroid cancer: results from a phase II study., J. Clin. Oncol.

  • CancerCommons: AXITINIB

    • Version: 25-July-2013

    Alternate Names:
    Axitinib PubChem Drug Name
    6450551 PubChem Drug ID
    Inlyta Drug Trade Name

    Drug Info:
    Drug Class Kinase Inhibitor
    Source Reported Drug Name(s) Axitinib/AG013736/Inlyta
    Pharmaceutical Developer Novartis

    Publications:

  • MyCancerGenome: AXITINIB

    • Version: 20-Jun-2017

    Alternate Names:
    AG-013736 Development Name
    AXITINIB Generic Name
    INLYTA Trade Name

    Drug Info:
    Drug Class Kinase Inhibitors
    FDA Approval Renal cell carcinoma

    Publications:

  • TdgClinicalTrial: AXITINIB

    • Version: January-2014

    Alternate Names:

    Drug Info:
    Drug Indications antineoplastic agent
    Drug Class Small molecule
    FDA Approval approved

    Publications:

  • PharmGKB: axitinib

    • Version: 18-August-2020

    Alternate Names:

    Drug Info:

    Publications:
    Maitland ML et al., 2010, Vascular endothelial growth factor pathway., Pharmacogenet Genomics
    Zientek MA et al., 2016, In Vitro Kinetic Characterization of Axitinib Metabolism., Drug Metab Dispos
    Ehmann F et al., 2014, European Medicines Agency initiatives and perspectives on pharmacogenomics., Br J Clin Pharmacol

  • CIViC: AXITINIB

    • Version: 14-September-2020

    Alternate Names:

    Drug Info:

    Publications:
    Pemovska T et al., 2015, Axitinib effectively inhibits BCR-ABL1(T315I) with a distinct binding conformation., Nature

  • TALC: AXITINIB

    • Version: 12-May-2016

    Alternate Names:
    AXITINIB Primary Drug Name
    AXITINIB Drug Generic Name
    INLYTA Drug Trade Name

    Drug Info:

    Publications:

  • GuideToPharmacology: 178102287

    • Version: 29-September-2020

    Alternate Names:
    AXITINIB GuideToPharmacology Ligand Name

    Drug Info:

    Publications:

  • DTC: AXITINIB

    • Version: 02-September-2020

    Alternate Names:
    CHEMBL1289926 ChEMBL Drug ID

    Drug Info:

    Publications:

  • TTD: Axitinib

    • Version: 2020.06.01

    Alternate Names:
    D01ZRI TTD Drug ID

    Drug Info:

    Publications:

  • ChemblDrugs: chembl:CHEMBL1289926

    • Version: ChEMBL_27

    Alternate Names:

    Drug Info:

    Publications:

  • MyCancerGenomeClinicalTrial: AXITINIB

    • Version: 30-February-2014

    Alternate Names:

    Drug Info:

    Publications:

  • CGI: Axitinib

    • Version: 27-September-2017

    Alternate Names:

    Drug Info:

    Publications:

  • ChemblInteractions: CHEMBL1289926

    • Version: chembl_23

    Alternate Names:

    Drug Info:

    Publications:

Disclaimer: This resource is intended for purely research purposes. It should not be used for emergencies or medical or professional advice.

A finding of a drug-gene interaction or potentially druggable category does not necessarily indicate effectiveness (or lack thereof) of any drug or treatment regimen. A finding of no interaction or no potentially druggable category does not necessarily indicate lack of effectiveness of any drug or treatment regimen. Drug-gene interactions or potentially druggable categories are not presented in ranked order of potential or predicted efficacy.

The dgidb.org website does not provide any medical or healthcare products, services or advice, and is not for medical emergencies or urgent situations. IF YOU THINK YOU MAY HAVE A MEDICAL EMERGENCY, CALL YOUR DOCTOR OR 911 IMMEDIATELY. Information contained on this website is not a substitute for a doctor's medical judgment or advice. We recommend that you discuss your specific, individual health concerns with your doctor or health care professional.

DGIdb (v4.2.0 - sha1 afd9f30b) • Last updated 2020-10-21